BIOD351 Module 9 Specialty Medications
Comprehensive Final Test (Qns & Ans)
2025
Question 1 (Multiple Choice)
Question:
Which property of monoclonal antibody therapies most
contributes to their prolonged half-life in patients?
A) Extensive hepatic metabolism
B) Fc receptor (FcRn) recycling
C) Rapid renal excretion
D) High-volume distribution to adipose tissue
Correct ANS:
B) Fc receptor (FcRn) recycling
©2025
, Rationale:
Monoclonal antibodies gain a prolonged half-life primarily
through interaction with the neonatal Fc receptor (FcRn), which
salvages them from lysosomal degradation and recycles them
back into the circulation. This mechanism is a key differentiator
from small molecule drugs.
---
Question 2 (Fill in the Blank)
Question:
Biosimilars are designed to be highly similar to their reference
biologic products, with no clinically meaningful differences in
______ and ______.
Correct ANS:
safety; efficacy
Rationale:
To gain regulatory approval, biosimilars must demonstrate that
they have comparable safety and efficacy profiles to the originator
biologic. Minor differences in inactive components are
permissible provided these do not affect clinical performance.
©2025
,---
Question 3 (True/False)
Question:
True/False: Biologic specialty medications are primarily
metabolized by cytochrome P450 enzymes in the liver.
Correct ANS:
False
Rationale:
Biologic drugs such as monoclonal antibodies and therapeutic
proteins are not metabolized by cytochrome P450 enzymes;
instead, they are broken down by proteolytic enzymes into smaller
peptides and amino acids. This distinction affects how they
interact with other drugs.
---
Question 4 (Multiple Response)
©2025
, Question:
Select all factors that may influence the immunogenicity of
biologic specialty medications:
A) Glycosylation patterns and structural modifications
B) Formation of protein aggregates during manufacturing or
storage
C) Route of administration (e.g., subcutaneous vs. intravenous)
D) Co-administration of immunosuppressive agents
E) Metabolism via hepatic CYP450 enzymes
Correct ANS:
A) Glycosylation patterns and structural modifications,
B) Formation of protein aggregates during manufacturing or
storage,
C) Route of administration,
D) Co-administration of immunosuppressive agents
Rationale:
Immunogenicity can be affected by the molecule’s structural
features (e.g., glycosylation, aggregates), the administration route
(which may affect immune exposure), and concomitant
©2025
Comprehensive Final Test (Qns & Ans)
2025
Question 1 (Multiple Choice)
Question:
Which property of monoclonal antibody therapies most
contributes to their prolonged half-life in patients?
A) Extensive hepatic metabolism
B) Fc receptor (FcRn) recycling
C) Rapid renal excretion
D) High-volume distribution to adipose tissue
Correct ANS:
B) Fc receptor (FcRn) recycling
©2025
, Rationale:
Monoclonal antibodies gain a prolonged half-life primarily
through interaction with the neonatal Fc receptor (FcRn), which
salvages them from lysosomal degradation and recycles them
back into the circulation. This mechanism is a key differentiator
from small molecule drugs.
---
Question 2 (Fill in the Blank)
Question:
Biosimilars are designed to be highly similar to their reference
biologic products, with no clinically meaningful differences in
______ and ______.
Correct ANS:
safety; efficacy
Rationale:
To gain regulatory approval, biosimilars must demonstrate that
they have comparable safety and efficacy profiles to the originator
biologic. Minor differences in inactive components are
permissible provided these do not affect clinical performance.
©2025
,---
Question 3 (True/False)
Question:
True/False: Biologic specialty medications are primarily
metabolized by cytochrome P450 enzymes in the liver.
Correct ANS:
False
Rationale:
Biologic drugs such as monoclonal antibodies and therapeutic
proteins are not metabolized by cytochrome P450 enzymes;
instead, they are broken down by proteolytic enzymes into smaller
peptides and amino acids. This distinction affects how they
interact with other drugs.
---
Question 4 (Multiple Response)
©2025
, Question:
Select all factors that may influence the immunogenicity of
biologic specialty medications:
A) Glycosylation patterns and structural modifications
B) Formation of protein aggregates during manufacturing or
storage
C) Route of administration (e.g., subcutaneous vs. intravenous)
D) Co-administration of immunosuppressive agents
E) Metabolism via hepatic CYP450 enzymes
Correct ANS:
A) Glycosylation patterns and structural modifications,
B) Formation of protein aggregates during manufacturing or
storage,
C) Route of administration,
D) Co-administration of immunosuppressive agents
Rationale:
Immunogenicity can be affected by the molecule’s structural
features (e.g., glycosylation, aggregates), the administration route
(which may affect immune exposure), and concomitant
©2025
